Prevention of Herpes Simplex Virus Induced Stromal Keratitis by a Glycoprotein B-Specific Monoclonal Antibody
Open Access
- 14 January 2015
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (1) , e0116800
Abstract
The increasing incidence of acyclovir (ACV) and multidrug-resistant strains in patients with corneal HSV-1 infections leading to Herpetic Stromal Keratitis (HSK) is a major health problem in industrialized countries and often results in blindness. To overcome this obstacle, we have previously developed an HSV-gB-specific monoclonal antibody (mAb 2c) that proved to be highly protective in immunodeficient NOD/SCID-mice towards genital infections. In the present study, we examined the effectivity of mAb 2c in preventing the immunopathological disease HSK in the HSK BALB/c mouse model. Therefore, mice were inoculated with HSV-1 strain KOS on the scarified cornea to induce HSK and subsequently either systemically or topically treated with mAb 2c. Systemic treatment was performed by intravenous administration of mAb 2c 24 h prior to infection (pre-exposure prophylaxis) or 24, 40, and 56 hours after infection (post-exposure immunotherapy). Topical treatment was performed by periodical inoculations (5 times per day) of antibody-containing eye drops as control, starting at 24 h post infection. Systemic antibody treatment markedly reduced viral loads at the site of infection and completely protected mice from developing HSK. The administration of the antiviral antibody prior or post infection was equally effective. Topical treatment had no improving effect on the severity of HSK. In conclusion, our data demonstrate that mAb 2c proved to be an excellent drug for the treatment of corneal HSV-infections and for prevention of HSK and blindness. Moreover, the humanized counterpart (mAb hu2c) was equally effective in protecting mice from HSV-induced HSK when compared to the parental mouse antibody. These results warrant the future development of this antibody as a novel approach for the treatment of corneal HSV-infections in humans.Keywords
This publication has 59 references indexed in Scilit:
- Overcoming drug-resistant herpes simplex virus (HSV) infection by a humanized antibodyProceedings of the National Academy of Sciences, 2013
- Everolimus improves experimental autoimmune uveoretinitisExperimental Eye Research, 2012
- Single‐cell analysis of population context advances RNAi screening at multiple levelsMolecular Systems Biology, 2012
- Ocular Distribution, Spectrum of Activity, and In Vivo Viral Neutralization of a Fully Humanized Anti-Herpes Simplex Virus IgG Fab Fragment following Topical ApplicationAntimicrobial Agents and Chemotherapy, 2012
- Corneal Penetration of Topical and Subconjunctival BevacizumabInvestigative Ophthalmology & Visual Science, 2011
- Impact of Valency of a Glycoprotein B-Specific Monoclonal Antibody on Neutralization of Herpes Simplex VirusJournal of Virology, 2011
- Characterisation of the epitope for a herpes simplex virus glycoprotein B-specific monoclonal antibody with high protective capacityMedical Microbiology and Immunology, 2010
- Distribution of Herpes Simplex Virus Type 1 and Varicella Zoster Virus in Ganglia of the Human Head and NeckThe Journal of Infectious Diseases, 2009
- Potentially Exposed but Uninfected Individuals Produce Cytotoxic and Polyfunctional Human Immunodeficiency Virus Type 1-Specific CD8+T-Cell Responses Which Can Be Defined to the Epitope LevelClinical and Vaccine Immunology, 2008
- Eclipse Phase of Herpes Simplex Virus Type 1 Infection: Efficient Dynein-Mediated Capsid Transport without the Small Capsid Protein VP26Journal of Virology, 2006